Key Considerations For Automating A Cell Therapy Manufacturing Program At Different Stages Of Development

Delve into the dynamic transition towards automation in cell and gene therapy manufacturing. In this webinar, industry leaders emphasize the fine balance between rapid clinical trials and sustainable scalability, and the crucial role of evaluating each process step for its impact on cell viability. They discuss the limitations of generic solutions in autologous cell therapy manufacturing and the need for tailored solutions, as well as the importance of client engagement on the technical and scientific aspects of process development. Highlighting the necessity for continuous innovation and balancing standardization with customization, the discussion concludes with the recognition that while investment in automation is vital, the associated high costs pose a challenge for start-ups.